MXPA05005340A - Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen. - Google Patents

Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.

Info

Publication number
MXPA05005340A
MXPA05005340A MXPA05005340A MXPA05005340A MXPA05005340A MX PA05005340 A MXPA05005340 A MX PA05005340A MX PA05005340 A MXPA05005340 A MX PA05005340A MX PA05005340 A MXPA05005340 A MX PA05005340A MX PA05005340 A MXPA05005340 A MX PA05005340A
Authority
MX
Mexico
Prior art keywords
medicines
pharmaceutical compositions
same
compositions containing
receptor antagonist
Prior art date
Application number
MXPA05005340A
Other languages
English (en)
Inventor
Heckmann Bertrand
Original Assignee
Proskelia Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proskelia Sas filed Critical Proskelia Sas
Publication of MXPA05005340A publication Critical patent/MXPA05005340A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion tiene por objeto los compuestos de la formula (I): en la que R1, R2, R3, R4 y G tienen los significados indicados en la descripcion, sus procedimientos de preparacion, sus aplicaciones como medicamentos que tienen una actividad antagonista del receptor de la vitronectina, y los compuestos farmaceuticos que los contienen.
MXPA05005340A 2002-11-19 2003-11-12 Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen. MXPA05005340A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0214429A FR2847254B1 (fr) 2002-11-19 2002-11-19 Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
PCT/FR2003/003349 WO2004048375A1 (fr) 2002-11-19 2003-11-12 Nouveaux derives antagonistes du recepteur de la vitronectine leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
MXPA05005340A true MXPA05005340A (es) 2005-11-17

Family

ID=32187700

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05005340A MXPA05005340A (es) 2002-11-19 2003-11-12 Nuevos derivados antagonistas del receptor de la vitronectina, sus procedimientos de preparacion, su aplicacion como medicamentos y los compuestos farmaceuticos que los contienen.

Country Status (28)

Country Link
US (2) US7582640B2 (es)
EP (2) EP2070914B1 (es)
JP (1) JP4567459B2 (es)
KR (1) KR101140752B1 (es)
CN (2) CN1738817B (es)
AR (2) AR042068A1 (es)
AT (2) ATE518842T1 (es)
AU (2) AU2003299330B2 (es)
BR (1) BR0316307A (es)
CA (1) CA2506310C (es)
CO (1) CO5700761A2 (es)
CY (1) CY1112218T1 (es)
DE (1) DE60327712D1 (es)
DK (2) DK1565467T3 (es)
ES (2) ES2369561T3 (es)
FR (1) FR2847254B1 (es)
HK (2) HK1076277A1 (es)
IL (2) IL168136A (es)
MA (1) MA27492A1 (es)
MX (1) MXPA05005340A (es)
NO (1) NO20052491D0 (es)
PL (1) PL376866A1 (es)
PT (2) PT1565467E (es)
RU (1) RU2412185C2 (es)
SI (2) SI1565467T1 (es)
TW (1) TW200412969A (es)
WO (1) WO2004048375A1 (es)
ZA (1) ZA200502850B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine
US20110189174A1 (en) 2010-02-01 2011-08-04 Afshin Shafiee Compositions and methods for treating, reducing, ameliorating, alleviating, or inhibiting progression of, pathogenic ocular neovascularization
US20110237605A1 (en) * 2010-03-26 2011-09-29 Eric Phillips Molecular Crystal of (4-(1,8-Naphthyridin-2-YL)Piperidin-1-YL)Pyrimidine Derivative
HUE051802T2 (hu) 2018-08-17 2021-03-29 Oxurion NV Integrin antagonisták
WO2021165206A1 (en) 2020-02-19 2021-08-26 Oxurion NV Treatment of dry amd with integrin antagonists
EP4171212A1 (en) 2020-06-29 2023-05-03 Ickovic & Bliss, Inc. Systems, methods, and program products for digital pet identification

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204350A (en) 1991-08-09 1993-04-20 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of n-heterocyclicalkyl-substituted phenyl derivatives
US5217994A (en) 1991-08-09 1993-06-08 Merck & Co., Inc. Method of inhibiting osteoclast-mediated bone resorption by administration of aminoalkyl-substituted phenyl derivatives
AU674553B2 (en) 1992-10-14 1997-01-02 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994012181A1 (en) 1992-12-01 1994-06-09 Merck & Co., Inc. Fibrinogen receptor antagonists
AU701776B2 (en) 1994-05-27 1999-02-04 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
PL318199A1 (en) 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
JPH10504807A (ja) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
AU3343097A (en) 1996-06-28 1998-01-21 Merck Patent Gmbh Phenylalamine derivatives as integrin inhibitors
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
US6723727B1 (en) 1996-12-20 2004-04-20 Hoechst Aktiengesellschaft Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
EP0933367A1 (en) * 1997-12-19 1999-08-04 Hoechst Marion Roussel Deutschland GmbH Novel acylguanidine derivates as inhibitors of bone resorption and as vitronectin receptor antagonists
HUP0100520A3 (en) 1998-01-23 2002-11-28 Genentech Inc Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion
CA2333927A1 (en) * 1998-04-01 1999-10-07 Dupont Pharmaceuticals Company Pyrimidines and triazines as integrin antagonists
JP2002522360A (ja) * 1998-08-07 2002-07-23 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体アンタゴニスト
JP2003502373A (ja) 1999-06-23 2003-01-21 メルク エンド カムパニー インコーポレーテッド インテグリン受容体アンタゴニスト
EP1065208A1 (en) * 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Substituted purine derivatives as inhibitors of cell adhesion
EP1065207A1 (en) 1999-07-02 2001-01-03 Aventis Pharma Deutschland GmbH Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them
IL148647A (en) * 1999-10-05 2005-06-19 Beers Ind Diamond Proprietary Growth of diamond clusters
DE10042655A1 (de) * 2000-08-31 2002-03-14 Aventis Pharma Gmbh Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion
FR2847254B1 (fr) 2002-11-19 2005-01-28 Aventis Pharma Sa Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant
FR2870541B1 (fr) * 2004-05-18 2006-07-14 Proskelia Sas Derives de pyrimidines antigonistes du recepteur de la vitronectine

Also Published As

Publication number Publication date
IL205693A (en) 2011-06-30
RU2412185C2 (ru) 2011-02-20
MA27492A1 (fr) 2005-08-01
US7763621B2 (en) 2010-07-27
ES2325616T3 (es) 2009-09-10
CA2506310A1 (fr) 2004-06-10
CN1738817B (zh) 2011-12-21
NO20052491L (no) 2005-05-23
WO2004048375A1 (fr) 2004-06-10
SI1565467T1 (sl) 2009-10-31
PT2070914E (pt) 2011-10-12
DK1565467T3 (da) 2009-09-14
HK1076277A1 (en) 2006-01-13
FR2847254A1 (fr) 2004-05-21
RU2005119163A (ru) 2006-02-27
SI2070914T1 (sl) 2012-02-29
CO5700761A2 (es) 2006-11-30
EP2070914A1 (fr) 2009-06-17
TW200412969A (en) 2004-08-01
CN101928287A (zh) 2010-12-29
ATE431825T1 (de) 2009-06-15
CY1112218T1 (el) 2015-12-09
US20090149476A1 (en) 2009-06-11
JP2006508999A (ja) 2006-03-16
HK1129372A1 (en) 2009-11-27
AR042068A1 (es) 2005-06-08
CA2506310C (fr) 2014-04-08
PT1565467E (pt) 2009-07-15
EP1565467B1 (fr) 2009-05-20
ZA200502850B (en) 2005-10-25
AU2009212779A1 (en) 2009-09-17
US20060052398A1 (en) 2006-03-09
EP1565467A1 (fr) 2005-08-24
AU2003299330A1 (en) 2004-06-18
NO20052491D0 (no) 2005-05-23
DK2070914T3 (da) 2011-11-21
EP2070914B1 (fr) 2011-08-03
FR2847254B1 (fr) 2005-01-28
AU2003299330B2 (en) 2009-09-17
JP4567459B2 (ja) 2010-10-20
PL376866A1 (pl) 2006-01-09
AR077476A2 (es) 2011-08-31
DE60327712D1 (de) 2009-07-02
ATE518842T1 (de) 2011-08-15
ES2369561T3 (es) 2011-12-01
AU2009212779B2 (en) 2011-09-01
US7582640B2 (en) 2009-09-01
KR101140752B1 (ko) 2012-05-03
CN1738817A (zh) 2006-02-22
KR20050083926A (ko) 2005-08-26
BR0316307A (pt) 2005-09-27
IL168136A (en) 2012-06-28

Similar Documents

Publication Publication Date Title
MY122392A (en) Adamantane derivatives of use of p2x7 receptor antagonists, a process for their preparation, pharmaceutical compositions containing them and a process for preparing the pharmaceutical compositions
SE0104140D0 (sv) Novel Compounds
SE9904505D0 (sv) Novel compounds
SE0200920D0 (sv) Novel compounds
SE9904738D0 (sv) Novel compounds
IL150085A0 (en) New-p2x7 receptor antagonists for use in the treatment of inflammatory, immune or cardiovascular diseases
ES2154167A1 (es) Aminoderivados ciclicos antagonistas del receptor ccr-3.
MXPA05008690A (es) Derivados de adamantano, procedimientos para su preparacion y composiciones farmaceuticas que los contienen.
MY127718A (en) Dolastatin 10 derivatives.
JO2353B1 (en) New derivatives of mixed-ring fluoroglycosides and drugs containing these compounds and their use
ATE316083T1 (de) Adamantanderivate
RS99804A (en) Novel compounds and their use
TW200616636A (en) Novel compounds
TW200639156A (en) New compounds
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
WO2003053945A3 (en) Urea derivatives and their use as vanilloid receptor antagonists
NO20020282D0 (no) Nytt difenylpiperidinderivat
IL157540A (en) Pharmaceutical compositions comprising n-(aryl)-2-arylethenesulfonamides, some such novel compounds and process for their preparation
HK1129372A1 (en) New antagonist derivatives of the vitronectin receptor, method for their preparation, their application as medicine and pharmaceutical compositions containing them
MXPA04005076A (es) Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico.
MXPA04005313A (es) Derivados de aminotetralin como antagonistas del receptor muscarinico.
WO2001010860A3 (en) Quinazolinone and azaquinazolinone derivatives
MXPA04005484A (es) Procedimiento de preparacion de derivados de equinocandina.
MY140653A (en) Substituted diketopiperazines and their use as oxytocyn antagonists
SE0202693D0 (sv) Compounds

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights